MPM Bioimpact LLC Reduces Stock Position in Aquestive Therapeutics, Inc. (NASDAQ:AQST)

MPM Bioimpact LLC reduced its position in shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) by 10.3% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,611,833 shares of the company's stock after selling 184,917 shares during the quarter. MPM Bioimpact LLC owned approximately 1.77% of Aquestive Therapeutics worth $5,738,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Raymond James Financial Inc. bought a new stake in Aquestive Therapeutics during the 4th quarter valued at $498,000. Harvey Capital Management Inc. raised its holdings in Aquestive Therapeutics by 1,419.3% in the 4th quarter. Harvey Capital Management Inc. now owns 267,390 shares of the company's stock worth $952,000 after purchasing an additional 249,790 shares in the last quarter. Vanguard Group Inc. raised its holdings in Aquestive Therapeutics by 1.9% in the 4th quarter. Vanguard Group Inc. now owns 4,346,754 shares of the company's stock worth $15,474,000 after purchasing an additional 82,958 shares in the last quarter. Renaissance Technologies LLC raised its holdings in Aquestive Therapeutics by 233.6% in the 4th quarter. Renaissance Technologies LLC now owns 95,400 shares of the company's stock worth $340,000 after purchasing an additional 66,800 shares in the last quarter. Finally, SG Americas Securities LLC raised its holdings in Aquestive Therapeutics by 28.7% in the 4th quarter. SG Americas Securities LLC now owns 32,966 shares of the company's stock worth $117,000 after purchasing an additional 7,347 shares in the last quarter. 32.45% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

AQST has been the subject of several research reports. Lake Street Capital decreased their price objective on shares of Aquestive Therapeutics from $10.00 to $8.00 and set a "buy" rating for the company in a report on Friday, March 7th. Raymond James set a $7.00 price objective on shares of Aquestive Therapeutics in a report on Friday, March 7th. Alliance Global Partners reaffirmed a "buy" rating on shares of Aquestive Therapeutics in a research report on Friday, March 7th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $10.00 target price on shares of Aquestive Therapeutics in a research report on Thursday. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has an average rating of "Buy" and an average price target of $10.67.

Aquestive Therapeutics Stock Performance

AQST stock remained flat at $2.38 during trading on Friday. 2,580,850 shares of the company traded hands, compared to its average volume of 1,506,208. Aquestive Therapeutics, Inc. has a one year low of $2.12 and a one year high of $5.80. The stock has a 50-day simple moving average of $2.76 and a 200 day simple moving average of $3.36. The stock has a market capitalization of $236.38 million, a PE ratio of -5.29 and a beta of 2.02.

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last announced its quarterly earnings data on Monday, May 12th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.07). The company had revenue of $8.72 million for the quarter, compared to the consensus estimate of $12.23 million. As a group, equities research analysts anticipate that Aquestive Therapeutics, Inc. will post -0.46 EPS for the current fiscal year.

Aquestive Therapeutics Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.